2016 Symposium Group photo

Making a Difference

The SSADH community is made up of families, scientists and doctors from around the world working together to make a better life for this very special patient population.

Our Mission

The SSADH Association is a voluntary, not-for-profit, 501(c) (3) organization dedicated to helping children and families affected by an ultra-rare neurometabolic disorder known as Succinic Semialdehyde Dehydrogenase Deficiency or SSADH.

The SSADH Association is committed to those affected with this neurotransmitter disease through education, advocacy and research.

News & Updates

Announcing SSADH Conference

May 19, 2020

The SSADH Conference that was planned for Boston this July has been moved to a virtual format. The event will…

Read More

Added Natural History Study Site Locations

January 9, 2020

We are pleased to announce that we have opened sites in Barcelona, Spain and Oslo and Gottingen, Germany for patients…

Read More

2019 Chip for Charity

October 2, 2019

We want to thank all those who participated in the 21st Annual Chip for Charity golf outing. Those of you who were able to join us know that we didn’t have our usual great weather, and even though it was misty, foggy and rather chilly, it didn’t keep anyone away.

Read More

Dried Bloodspots Facilitates SSADH Newborn Detection

August 1, 2019

Gamma-Hydroxybutyrate Content in Dried Bloodspots Facilitates Newborn Detection of Succinic Semialdehyde Dehydrogenase Deficiency. Further, development of a first-tier screening method…

Read More

The research team of Drs. Gibson and Roullet makes the news in the WSU Insider.  An article titled, Worldwide Rare Disease Study Led by WSU Researchers, by Judith Van Dongen, WSU Spokane Office of Research, talks about the grant received from the National Institute of Child Health and Human Development to conduct a natural history study for SSADH patients.

The article details the importance of the natural history study and explains how it will help the scientists identify specific biomarkers of disease severity and better predict the natural course of SSADH. Additionally, the article talks about the importance of the natural history study and explains how it will meet prerequisites for FDA approval of new drugs or existing drugs indicated for other conditions.

Click here to read the entire story.

Mike Gibson, far left, and Jean‑Baptiste Roullet (blue sweater) and their team of researchers in the WSU College of Pharmacy and Pharmaceutical Sciences.
(Photo by Cori Kogan, WSU Spokane)

For more information or to enroll in the study please email:
Study Coordinator:  Dr. Melissa DiBacco by email at: Melissa.Dibacco@childrens.harvard.edu
Study Coordinator:  Dr. Kathrin Jeltsch by email at: Kathrin.Jeltsch@med.uni-heidelberg.de


WSU Team Picture